TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37367978
Drug: Alteplase: intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase: intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.
Study: 37368100
Drug: Adavosertib 225
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 225 mg twice daily on days 1-2 at 12-h intervals and once on day 3.
Study: 37368401
Drug: App-based individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based individually tailored self-management support (SELFBACK) adjunct to usual care
Study: 37368401
Drug: Web-based nontailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based nontailored self-management support (e-Help) adjunct to usual care
Study: 37368512
Drug: Higher BMI
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher BMI (in models including both BMI and insulin sensitivity)
Study: 37368929
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with oral etoposide chemotherapy
Study: 37368929
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) alone
Study: 37368929
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum biomarkers (CRP, IL-6, IL-10, soluble tumor necrosis factor receptor-2)
Study: 37369081
Drug: EV monotherapy
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV monotherapy
Study: 37369232
Drug: Orforglipron (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orforglipron (12 mg or greater)
Study: 37369421
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of high-velocity, soft-tissue massage, and craniosacral techniques
Study: 37369422
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days antibiotic therapy
Study: 37369422
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days antibiotic therapy
Study: 37369815
Drug: IO-tyrosine kinase
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO-tyrosine kinase inhibitor (IO + TKI) combinations
Study: 37369815
Drug: Dual immuno-oncology
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual immuno-oncology (IO + IO) therapy
Study: 37369826
Drug: Basal long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal long-acting insulin
Study: 37369955
Drug: Difelikefalin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin (single intravenous doses)
Study: 37370032
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan), up to 5 cycles.
Study: 37370032
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with mFOLFOXIRI
Study: 37370174
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC) TB treatment + placebo
Study: 37370174
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC) TB treatment + acetylsalicylic acid (ASA)
Study: 37370174
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC) TB treatment + ibuprofen (Ibu)
Study: 37370204
Drug: Facilitated allogeneic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated allogeneic hematopoietic stem cell transplant with tolerogenic CD8 + /T-cell receptor - facilitating cells (FCR001) and low-dose, nonmyeloablative conditioning.
Study: 37373625
Drug: E4 15
Normalized name: Ethinylestradiol 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E4 15 mg once daily for 21 days
Study: 37373857
Drug: Pneumatic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pneumatic compression combined with standard venous thromboembolism (VTE) therapy
Study: 37373857
Drug: Standard venous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard venous thromboembolism (VTE) therapy (control group)
Study: 37375656
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of oligomalt (180 g/day)
Study: 37375656
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of oligomalt (80 g/day) + maltodextrin (100 g/day)
Study: 37375656
Drug: Maltodextrin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (180 g/day)
Study: 37376480
Drug: PXVX0047 (Ad4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXVX0047 (Ad4 and Ad7 components administered orally in a single dose to 11 subjects)
Study: 37376480
Drug: Control Ad4/Ad7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Ad4/Ad7 vaccine (currently in use by the US military, administered to 3 subjects)
Study: 37376989
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol <70 mg/dL with >50% LDL cholesterol reduction from baseline
Study: 37376989
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol <70 mg/dL with <50% LDL cholesterol reduction from baseline
Study: 37376989
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol 100±10 mg/dL
Study: 37377385
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg daily
Study: 37377385
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg subcutaneously weekly
Study: 37377613
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily
Study: 37377890
Drug: Intravenous RNA-electroporated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RNA-electroporated cMET-directed CAR T cells (1 × 10e8 T cells/dose, up to six infusions)
Study: 37377890
Drug: Intravenous RNA-electroporated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RNA-electroporated cMET-directed CAR T cells
Study: 37378754
Drug: eptinezumab 100
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptinezumab 100 mg, 300 mg
Study: 37378806
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIg) at 2.0 g/kg induction dose followed by maintenance doses of 0.5, 1.0 or 2.0 g/kg every 3 weeks for 24 weeks
Study: 37378860
Drug: CC-90001 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90001 (100, 200, or 400 mg) administered once daily for 12 weeks
Study: 37378972
Drug: Pharmacotherapy (varenicline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (varenicline, dual-form nicotine replacement, or their combination) and behavioral smoking cessation intervention with weight management and physical activity support
Study: 37378974
Drug: Cognitive-Behavioral Case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Case Management (CBCM) with Fluoxetine for 26 weeks
Study: 37379001
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of antibiotics
Study: 37379158
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus platinum-based chemotherapy (experimental group)
Study: 37379495
Drug: Gilteritinib 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib 120 mg once daily
Study: 37379495
Drug: Gilteritinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib as single-agent maintenance therapy
Study: 37379502
Drug: Lazertinib 240
Normalized name: lazertinib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240 mg once daily orally
Study: 37379502
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg once daily orally
Study: 37379532
Drug: Sputnik V
Normalized name: Sputnik V
DrugBank: Gam-COVID-Vac (DB15848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputnik V vaccine
Study: 37379532
Drug: Ocrelizumab treatment
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab treatment
Study: 37379764
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus binimetinib 45 mg
Study: 37379764
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus binimetinib 30 mg
Study: 37379764
Drug: Talazoparib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib plus binimetinib 45 mg
Study: 37379764
Drug: Talazoparib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib plus binimetinib 30 mg
Study: 37380156
Drug: ANDV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANDV DNA vaccine (2 mg) in a 3-dose schedule (days 1, 29, 169)
Study: 37380156
Drug: ANDV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANDV DNA vaccine (2 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Study: 37380156
Drug: ANDV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANDV DNA vaccine (4 mg) in a 3-dose schedule (days 1, 29, 169)
Study: 37380156
Drug: ANDV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANDV DNA vaccine (4 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Study: 37380211
Drug: TESLA-G (gamified
Approvals — FDA: no, EMA: no, PMDA: no
Description: TESLA-G (gamified quizzing platform)
Study: 37380211
Drug: TESLA-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: TESLA-G
Study: 37380226
Drug: Transcatheter edge-to-edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT)
Study: 37380226
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) alone without anticoagulation
Study: 37380364
Drug: Roxadustat (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (oral hypoxia-inducible factor prolyl hydroxylase inhibitor), administered three times weekly in-center for 24 weeks.
Study: 37380821
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion using vascular access button (VAB) technology for AZD5991
Study: 37381988
Drug: rNAPc2 (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: rNAPc2 (lower or higher dose)
Study: 37381988
Drug: Heparin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (standard of care)
Study: 37382155
Drug: mRNA vaccines
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccines BNT162b2 (Pfizer/BioNTech), mRNA1273 (Moderna) in two and three-dose regimens
Study: 37382155
Drug: Bivalent mRNA
Normalized name: Adult B and BA.4/BA.5 lineage SARS-CoV-2 bivalent mRNA only vaccine product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent mRNA vaccines
Study: 37382155
Drug: Individualization and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualization and adjustment of immunosuppressive drugs
Study: 37382794
Drug: FM-ACT (self-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM-ACT (self-guided digital acceptance and commitment therapy) for 12 weeks, n=39
Study: 37383763
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid prescription (ten 5 mg tablets oxycodone provided preoperatively)
Study: 37383763
Drug: Restricted opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted opioid prescription (opioid prescription provided only upon patient request postoperatively)
Study: 37383995
Drug: Wheat soya
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat soya blend plus (WSB+) during pregnancy and first six months of lactation, and lipid-based nutrient supplement - medium-quantity (LNS-MQ) between 6-23 months of age.
Study: 37384109
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and herbal supplement taken twice a day for 1 month
Study: 37384278
Drug: Microburst VNS
Normalized name: VN-rzyl
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microburst VNS in addition to standard anti-seizure medications
Study: 37384412
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily for 6 weeks
Study: 37384482
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders using Seeking Safety
Study: 37384482
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders (both interventions)
Study: 37384848
Drug: Zipalertinib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zipalertinib at various dose levels (30, 45, 65, 100, and 150 mg orally twice a day)
Study: 37384848
Drug: Zipalertinib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zipalertinib at 100 mg twice a day
Study: 37385272
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1
Study: 37385272
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid 1300 mg three times daily on days 1-5
Study: 37385279
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 50 mg
Study: 37385279
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 25 mg
Study: 37385280
Drug: Retatrutide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 0.5 mg
Study: 37385280
Drug: Retatrutide 4
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 4 mg escalation
Study: 38858523
Drug: Retatrutide 4
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 4 mg
Study: 37385280
Drug: Retatrutide 8
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 8 mg slow escalation
Study: 37385280
Drug: Retatrutide 8
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 8 mg fast escalation
Study: 37385280
Drug: Retatrutide 12
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 12 mg escalation
Study: 37385475
Drug: JNJ-56136379 75
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 75 mg monotherapy
Study: 37385475
Drug: JNJ-56136379 250
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 250 mg monotherapy
Study: 37385724
Drug: SEA-CD40 administered
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEA-CD40 administered intravenously at doses of 0.6, 3, 10, 30, 45, and 60 µg/kg in 21-day cycles.
Study: 37385724
Drug: SEA-CD40 administered
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEA-CD40 administered intravenously at doses of 10-30 µg/kg.
Study: 37385724
Drug: SEA-CD40 monotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEA-CD40 monotherapy.
Study: 37385747
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - combination of aspirin and P2Y
Study: 37386016
Drug: Milademetan (MDM2i)
Normalized name: Milademetan
DrugBank: Milademetan (DB15257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milademetan (MDM2i) with low-dose cytarabine (LDAC)
Study: 37386016
Drug: Milademetan (MDM2i)
Normalized name: Milademetan
DrugBank: Milademetan (DB15257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milademetan (MDM2i) with low-dose cytarabine (LDAC)±venetoclax
Study: 37386368
Drug: Physical therapy-led
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy-led triage
Study: 37386462
Drug: Antipsychotic-naïve and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-naïve and previously medicated participants
Study: 37386519
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 40 mg of hyperbaric prilocaine (Group A)
Study: 37386582
Drug: Deep neuromuscular
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular block (DNMB) with rocuronium bolus at 1.2 mg/kg and maintenance dose of 0.3-0.6 mg/kg/h
Study: 37386582
Drug: Moderate neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular block (MNMB) with rocuronium bolus at 0.6 mg/kg and maintenance dose in boluses of 0.15-0.25 mg/kg
Study: 37387798
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine administration at 1.5 mg/kg
Study: 37388233
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (HF-RT) - 40 Gy/15 fractions ± concomitant boost [8 Gy/15 fractions]
Study: 37388233
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (CF-RT) - 50 Gy/25 fractions ± sequential boost [10 Gy/5 fractions]
Study: 37388633
Drug: Flexitarian diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexitarian diet including approximately three serves of red meat (average of 390 g cooked weight per individual) per week
Study: 37388633
Drug: Vegetarian diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetarian diet including plant-based meat alternatives (350-400 g per individual) per week
Study: 37388902
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_High expression
Study: 37388902
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_Low expression
Study: 37389891
Drug: Bezlotoxumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezlotoxumab (10 mg/kg)
Study: 37389915
Drug: Purposeful Pathways
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purposeful Pathways intervention (augmented treatment condition)
Study: 37390800
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ctDNA MAF and carcinoembryonic antigen levels
Study: 37390836
Drug: ZPIV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV (two or three doses administered at days 0, 28, and 196-234)
Study: 37390836
Drug: ZPIV (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV (third dose)
Study: 37390836
Drug: ZPIV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV (two doses)
Study: 37390980
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus Olaparib (300 mg orally, twice daily)
Study: 37391367
Drug: Daily written
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily written patient care updates
Study: 37391381
Drug: Rapid steroid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid steroid withdrawal (RSWD)
Study: 37391381
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy
Study: 37391938
Drug: Anti-EGFR rechallenge
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR rechallenge (fourth-line therapy)
Study: 37391938
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (fourth-line therapy)
Study: 37391938
Drug: Anti-EGFR rechallenge
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR rechallenge (fourth-line treatment)
Study: 37391938
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (fourth-line treatment)
Study: 37392089
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (twice-a-week for 4 weeks, then once-a-week for 4 weeks)
Study: 37392789
Drug: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) 160/150/50 μg, once-daily (o.d.)
Study: 37392789
Drug: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) pooled (160/150/50 μg and 80/150/50 μg)
Study: 37392789
Drug: High-dose Mometasone/indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Mometasone/indacaterol (MF/IND) 320/150 μg, once-daily (o.d.)
Study: 37392789
Drug: High-dose Fluticasone/salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Fluticasone/salmeterol (FLU/SAL) 500/50 μg, twice-daily (b.i.d.)
Study: 37393237
Drug: Adjuvanted inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted inactivated influenza vaccine (aIIV3)
Study: 37393237
Drug: High-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inactivated influenza vaccine (HD-IIV3)